Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
655 JPY | -1.06% | -6.70% | +15.52% |
Income Statement Evolution (Annual data)
Fiscal Period: |
---|
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2020 Q3 | 2021 Q1 | 2021 Q3 | 2022 Q1 | 2022 Q3 | 2023 Q1 |
---|---|---|---|---|---|---|
Net sales 1 | 71 | 62 | 125 | 193 | 358 | 35 |
EBITDA | - | - | - | - | - | - |
EBIT 1 | -507 | -349 | -330 | -384 | -279 | -325 |
Operating Margin | -714.08% | -562.9% | -264% | -198.96% | -77.93% | -928.57% |
Earnings before Tax (EBT) 1 | -880 | -349 | -327 | -328 | -264 | -322 |
Net income 1 | -881 | -350 | -329 | -328 | -265 | -323 |
Net margin | -1,240.85% | -564.52% | -263.2% | -169.95% | -74.02% | -922.86% |
EPS 2 | -61.21 | -22.36 | -18.97 | -18.98 | -15.28 | -18.69 |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 20-11-06 | 21-05-07 | 21-11-05 | 22-05-13 | 22-11-04 | 23-05-12 |
Balance Sheet Analysis
Fiscal Period: |
---|
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+15.52% | 89M | |
-2.32% | 92.59B | |
+3.68% | 41.43B | |
-10.90% | 33.49B | |
-19.56% | 14.62B | |
-9.06% | 12.77B | |
-11.34% | 11.58B | |
-43.53% | 11.35B | |
+3.75% | 8.97B | |
-6.32% | 8.3B |
- Stock Market
- Equities
- 4588 Stock
- Financials Oncolys BioPharma Inc.